KLK13, KLKL4, KLK-13, Kallikrein-13
Recombinant Human KLK13 /Kallikrein-13 Protein (rhKallikrein-13 /KLK13) Gly 18 - Ile 262 (Accession # AAH69334) was produced in human 293 cells (HEK293) at ACROBiosystems.
rhKallikrein-13 /KLK13 is fused with 6×his tag at the C-terminus, and has a calculated MW of 28 kDa. The predicted N-terminus is Gly 18. DTT-reduced Protein migrates as 33-40 kDa in SDS-PAGE due to glycosylation.
Less than 1.0 EU per μg of the rhKallikrein-13 /KLK13 by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 20mM MES, 150mM NaCl, pH 6.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Kallikrein-13 (KLK13) is also known as Kallikrein-like protein 4 (KLK-L4), is a secreted protein, belongs to the peptidase S1 family and Kallikrein subfamily. KLK-13 contains one peptidase S1 domain. KLK13 is mainly expressed in prostate, breast, testis and salivary gland. KLK13 may be involved in the pathogenesis and / or progression of breast and ovary cancers, and is regarded as a novel cancer biomarker. In addition, KLK13 interacts and forms complexes with several serum protease inhibitors, such as alpha2-macroglobulin, and its expression is regulated by steroid hormones.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.